Skip to main content

Advertisement

SpringerLink
Log in

Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer

  • Preclinical Study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The involvement of the immune system for the course of breast cancer, as evidenced by varying degrees of lymphocyte infiltration (LI) into the tumor is still poorly understood. The aim of this study was to evaluate the prognostic value of LI in breast cancer samples using microarray-based screening for LI-associated genes. Starting from the observation that most published ER gene signatures are heavily influenced by the LI effect, we developed and applied a novel approach to dissect molecular signatures. Further, a meta-analysis encompassing 1,044 hybridizations showed that LI alone is not sufficient to highlight breast cancer patients with different prognosis. However, for ER positive patients, high LI was associated with shorter survival times, whereas for ER negative patients, high LI is significantly associated with longer survival. Annotation of LI, in addition to ER status, is important for breast cancer patient prognosis and may have implications for the future treatment of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. The R core project team (2007) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria

  2. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E et al (1992) Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28A:859–864. doi:10.1016/0959-8049(92)90134-N

    Article  PubMed  CAS  Google Scholar 

  3. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C et al (2007) High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 67:10669–10676. doi:10.1158/0008-5472.CAN-07-0539

    Article  PubMed  CAS  Google Scholar 

  4. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D et al (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204:1037–1047. doi:10.1084/jem.20061120

    Article  PubMed  CAS  Google Scholar 

  5. Asslaber M, Zatloukal K (2007) Biobanks: transnational, European and global networks. Brief Funct Genomic Proteomic 6:193–201

    Article  PubMed  Google Scholar 

  6. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545. doi:10.1016/S0140-6736(00)04046-0

    Article  PubMed  CAS  Google Scholar 

  7. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373–5380. doi:10.1200/JCO.2006.05.9584

    Article  PubMed  Google Scholar 

  8. Beissbarth T, Speed TP (2004) GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 20:1464–1465. doi:10.1093/bioinformatics/bth088

    Article  PubMed  CAS  Google Scholar 

  9. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J et al (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66:4636–4644. doi:10.1158/0008-5472.CAN-06-0031

    Article  PubMed  CAS  Google Scholar 

  10. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353–357. doi:10.1038/nature04296

    Article  PubMed  CAS  Google Scholar 

  11. Biswas DK, Singh S, Shi Q, Pardee AB, Iglehart JD (2005) Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE 2005:pe27. doi:10.1126/stke.2882005pe27

  12. Buness A, Huber W, Steiner K, Sultmann H, Poustka A (2005) arrayMagic: two-colour cDNA microarray quality control and preprocessing. Bioinformatics 21:554–556. doi:10.1093/bioinformatics/bti052

    Article  PubMed  CAS  Google Scholar 

  13. Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26:729–735. doi:10.1200/JCO.2007.14.3222

    Article  PubMed  Google Scholar 

  14. Clamp A, Danson S, Clemons M (2002) Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies. Lancet Oncol 3:611–619. doi:10.1016/S1470-2045(02)00875-6

    Article  PubMed  CAS  Google Scholar 

  15. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867. doi:10.1038/nature01322

    Article  PubMed  CAS  Google Scholar 

  16. Cox DR (1972) Regression models and life tables. J R Stat Soc [Ser A], 187–220

  17. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37. doi:10.1038/nrc1782

    Article  PubMed  CAS  Google Scholar 

  18. DeNardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9:212. doi:10.1186/bcr1746

    Google Scholar 

  19. Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T et al (2003) SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res 31:219–223. doi:10.1093/nar/gkg014

    Article  PubMed  CAS  Google Scholar 

  20. Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207–210. doi:10.1093/nar/30.1.207

    Article  PubMed  CAS  Google Scholar 

  21. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964. doi:10.1126/science.1129139

    Article  PubMed  CAS  Google Scholar 

  22. Griffith CD, Ellis IO, Bell J, Burns K, Blamey RW (1990) Density of lymphocytic infiltration of primary breast cancer does not affect short-term disease-free interval or survival. J R Coll Surg Edinb 35:289–292

    PubMed  CAS  Google Scholar 

  23. Hayes DF (2005) Prognostic and predictive factors revisited. Breast 14:493–499. doi:10.1016/j.breast.2005.08.023

    Article  PubMed  Google Scholar 

  24. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9:811–818. doi:10.1002/sim.4780090710

    Article  PubMed  CAS  Google Scholar 

  25. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H et al (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65. doi:10.1186/bcr1771

  26. Lash AE, Tolstoshev CM, Wagner L, Schuler GD, Strausberg RL, Riggins GJ et al (2000) SAGEmap: a public gene expression resource. Genome Res 10:1051–1060. doi:10.1101/gr.10.7.1051

    Article  PubMed  CAS  Google Scholar 

  27. Marques LA, Franco EL, Torloni H, Brentani MM, da Silva-Neto JB, Brentani RR (1990) Independent prognostic value of laminin receptor expression in breast cancer survival. Cancer Res 50:1479–1483

    PubMed  CAS  Google Scholar 

  28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184

    Article  PubMed  CAS  Google Scholar 

  29. Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N et al (1997) Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3:817–819

    PubMed  CAS  Google Scholar 

  30. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550–13555. doi:10.1073/pnas.0506230102

    Article  PubMed  CAS  Google Scholar 

  31. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S et al (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12:888–894

    PubMed  CAS  Google Scholar 

  32. Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, Drover S (2006) Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol 18:1591–1602. doi:10.1093/intimm/dxl092

    Article  PubMed  CAS  Google Scholar 

  33. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R et al (1991) Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44–49. doi:10.1002/ijc.2910490109

    Article  PubMed  CAS  Google Scholar 

  34. Schlingemann J, Thuerigen O, Ittrich C, Toedt G, Kramer H, Hahn M et al (2005) Effective transcriptome amplification for expression profiling on sense-oriented oligonucleotide microarrays. Nucleic Acids Res 33:e29. doi:10.1093/nar/gni029

  35. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments Stat Appl Genet Mol Biol 3:Article3

  36. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi:10.1073/pnas.191367098

    Article  PubMed  CAS  Google Scholar 

  37. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398. doi:10.1073/pnas.1732912100

    Article  PubMed  CAS  Google Scholar 

  38. Teschendorff AE, Journee M, Absil PA, Sepulchre R, Caldas C (2007) Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLOS Comput Biol 3:e161. doi:10.1371/journal.pcbi.0030161

  39. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8:R157. doi:10.1186/gb-2007-8-8-r157

  40. van‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. doi:10.1038/415530a

    Google Scholar 

  41. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009. doi:10.1056/NEJMoa021967

    Article  PubMed  Google Scholar 

  42. West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP et al (2005) Determination of stromal signatures in breast carcinoma. PLoS Biol 3:e187. doi:10.1371/journal.pbio.0030187

  43. Whitford P, Mallon EA, George WD, Campbell AM (1990) Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer 62:971–975

    PubMed  CAS  Google Scholar 

  44. Yao C, Lin Y, Ye CS, Bi J, Zhu YF, Wang SM (2007) Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin Med J (Engl) 120:1766–1772

    CAS  Google Scholar 

Download references

Acknowledgements

We thank Sabrina Balaguer-Puig for excellent technical assistance, Andreas Buness for retrieving the external datasets and Dirk Ledwinka for IT support. The study was supported by a grant of the German Federal Ministry for Education and Research (NGFN grant 01GR0418; NGFN grant 01GR0450) and the Austrian Genome Research Program (GEN-AU).

Authors contributions

MS, RK and TB had the initial ideas for the study. AC collected all the data and performed the experiments. TB did the statistical analysis with the help of AC and AB. MA, FP, KZ and HSa collected and reevaluated the patient samples creating the patient samples and annotation for our own dataset. AC, TB, RK, AP and HSü interpreted the results and wrote the manuscript. AC, RK, TB, AP and HSü contributed in discussions. All authors read and approved the final manuscript.

Author information

Authors and Affiliations

  1. Division of Molecular Genome Analysis, German Cancer Research Center, Im Neuenheimer Feld 580, 69120, Heidelberg, Germany

    Alberto Calabrò, Tim Beissbarth, Ruprecht Kuner, Michael Stojanov, Annemarie Poustka & Holger Sültmann

  2. Division of Biostatistic, German Cancer Research Center, 69120, Heidelberg, Germany

    Axel Benner

  3. Institutes of Pathology, Medical University of Graz, 8036, Graz, Austria

    Martin Asslaber & Kurt Zatloukal

  4. Clinical Oncology, Medical University of Graz, 8036, Graz, Austria

    Ferdinand Ploner & Hellmut Samonigg

Authors
  1. Alberto Calabrò
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tim Beissbarth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruprecht Kuner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Stojanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Axel Benner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin Asslaber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ferdinand Ploner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kurt Zatloukal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hellmut Samonigg
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Annemarie Poustka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Holger Sültmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holger Sültmann.

Additional information

Alberto Calabrò and Tim Beissbarth contributed equally to this manuscript.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calabrò, A., Beissbarth, T., Kuner, R. et al. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 116, 69–77 (2009). https://doi.org/10.1007/s10549-008-0105-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0105-3

Keywords

Search

Navigation